ObsEva is focused on advancing women's reproductive health through innovative therapeutics, particularly in the areas of uterine fibroids, endometriosis, assisted reproductive technology (ART), and preterm labor. The company is developing a pipeline of novel, orally-administered compounds, including Linzagolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist. Linzagolix is designed to effectively manage conditions such as heavy menstrual bleeding associated with uterine fibroids and pain related to endometriosis, while minimizing adverse effects like bone mineral density loss. Its unique formulation allows for personalized dosing, which can be tailored to individual patient responses, potentially leading to significant improvements in quality of life with fewer side effects.

In addition to Linzagolix, ObsEva is advancing nolasiban (OBE001), an oral oxytocin receptor antagonist aimed at enhancing the success rates of assisted reproductive technology. Nolasiban works by decreasing uterine contractions and improving blood flow to the uterus, thereby increasing the receptivity of the endometrium for embryo implantation. This innovative approach has the potential to significantly improve live-birth rates for patients undergoing ART, addressing a critical need in reproductive health. Through these advancements, ObsEva is committed to transforming the landscape of women's reproductive health and providing effective solutions for various reproductive health challenges.

Switzerland

Innovating Women’s Reproductive Health and Pregnancy Therapeutics

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. 

Urogenital Diseases

ObsEva

Preterm labor

ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F2α receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF2α is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin.

Ebopiprant (OBE022)

Endometriosis

Inflammatory disease

Yselty® (linzagolix) is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world.

YSELTY® (linzagolix)

Benign tumor

Linzagolix (previously known as OBE2109) is a novel, oral, once daily, GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product.

ObsEva

Company Details